

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

For:

Glucksmann et al.

09/495,823

Appl No.: Filed:

January 31, 2000

Examiner: 22438, 23553, 25278, AND 26212 NOVEL HUMAN SULFATASES

October 29, 2001

Group Art Unit:

Confirmation No.: 5331

1652

Y. Pak

Commissioner for Patents Washington, DC 20231

RESPONSE TO RESTRICTION REQUIREMENT

This is in response to the Office Action dated September 27, 2001, in which the Examiner has required restriction between Group I, namely Claims 243-249 and 254-255; Group II, namely Claims 250-252; Group III, namely Claim 253; Group IV, namely Claims 256-258; Group V, namely Claims 259-261; Group VI, namely Claims 262-263; Group VII, namely Claim 264; Group VIII, namely Claim 265; Group IX, namely Claim 266; and Group X, namely Claim 267. The Examiner further requires the election of one sulfatase of SEQ ID NO:1, 3, 5 or 7 or one DNA of SEQ ID NO:2, 4, 6. or 8. Applicant hereby provisionally elects without traverse to prosecute the claims of Group I (Claims 243-249 and 254-255) as directed to SEQ ID NO:8, and expressly reserves the right to file divisional applications or take such other appropriate measures deemed necessary to protect the inventions in the remaining claims.

Should the Examiner have further questions or comments with respect to examination of this case, it is respectfully requested that the Examiner telephone the undersigned attorney so that RECEIVED further examination of this application can be expedited.

FEB 1 4 2002

OFFICE OF PETITIONS

RTA01/2106093v1

In re: Glucksmann et al. Appl No.: 09/495,823 Filed: January 31, 2000

Page 2

It is not believed that extensions of time or fees for net addition of claims are required, beyond those, which may otherwise be provided for in documents accompanying this paper. However, in the event that additional extensions of time are necessary to allow consideration of this paper, such extensions are hereby petitioned under 37 CFR § 1.136(a), and any fee required therefore (including fees for net addition of claims) is hereby authorized to be charged to Deposit Account No. 16-0605.

Respectfully submitted,

Eric J. Kron

Registration No. 45,941

CUSTOMER NO. 00826 ALSTON & BIRD LLP

Bank of America Plaza 101 South Tryon Street, Suite 4000 Charlotte, NC 28280-4000 Tel Raleigh Office (919) 862-2200 Fax Raleigh Office (919) 862-2260

Nora C. Martinez


CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal service with sufficient postage as first class mail, in an envelope addressed to the Commissioner for Patents, Washington, DC 20231 on October 29, 2001.

RECEIVED

FEB 1 4 2002

OFFICE OF PETITIONS



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Appl No.:

Filed:

For:

Glucksmann et al.

09/495,823

January 31, 2000

Confirmation No.: 5331

Group Art Unit: 1652 Examiner:

Y. Pak

22438, 23553, 25278, AND 26212 NOVEL HUMAN SULFATASES

October 29, 2001

Commissioner for Patents Washington, DC 20231

PRELIMINARY AMENDMENT

Dear Sir:

Please amend the above-identified application as follows:

In The Specification:

On page 7, please replace paragraph 5 (lines 19-20) with the following paragraph:

Figure 1A and 1B shows the 22438 sulfatase cDNA sequence (SEQ ID NO:2) and the deduced amino acid sequence (SEQ ID NO:1).

On page 8, please replace paragraph 2 (lines 7-8) with the following paragraph:

Figure 5A, 5B and 5C shows the 23553 sulfatase cDNA sequence (SEQ ID NO:4) and the deduced amino acid sequence (SEQ ID NO:3).

On page 8, please replace paragraph 5 (lines 16-23) with the following paragraph:

Figure 8A and 8B shows an analysis of the 23553 sulfatase open reading frame for amino acids corresponding to specific functional sites. For the N-glycosylation sites, the actual modified residue is the first amino acid. For protein kinase C phosphorylation sites, the actual

RECEIVED

FEB 1 4 2002

OFFICE OF PETITIONS